Emerging Biopharma

Lilly
Biotech

Lilly inks $2.88B Merida buyout to expand autoimmune pipeline

The deal will give Lilly a beachhead in efforts to treat autoimmune disease through the selective degradation of pathogenic autoantibodies.
Nick Paul Taylor Aug 31, 2026 9:18am
Close-up of Benjamin Franklins eyes peering through hundred dollar bills

Pfizer vet debuts Khartis with sights set on thyroid eye disease

Aug 13, 2026 9:00am
cash money

Epicrispr bags $90M to rewrite treatment of rare muscle disease

Aug 11, 2026 10:30am
two arrows pointing different directions

Caldera hits Nasdaq via Synlogic reverse merger

Jul 29, 2026 8:56am
rocketship new blast off start up business development break off acquisition split

Lupin seeds US spinout with cash, clinical-stage cancer assets

Jul 21, 2026 8:20am
photo finish line

Biotechs forced to learn new patent tricks to protect pipelines

Jul 12, 2026 12:00pm
More News

Beeline bolsters autoimmune ambitions with $126M

Jun 30, 2026 7:00am

Merck KGaA pledges $50M to new biotech with eye to acquisition

Jun 23, 2026 10:16am

With $30M, Oorja Bio breathes new life into fibrosis candidate

May 20, 2026 10:31am

Nominations now open for Fierce Biotech's 2026 Fierce 15

May 18, 2026 9:44am